Clinical trials: Sirolimus, completed
Coronary Artery Disease
Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent
Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of "real-world" patients.
- Trial name
- Inspiron RL II (NCT03263260)
- Testing
- implant
- Where
- Brazil
- Volunteers
- 2,504 people
- Sponsor
- Scitech Produtos Medicos SA
Diabetic Retinopathy
Sirolimus to Treat Diabetic Macular Edema
Objective: Diabetic macular edema (DME) is a frequent manifestation of diabetic retinopathy, a leading cause of blindness in the United States. The only proven treatment for DME is laser photocoagulation.
- Trial name
- SDME (NCT00711490)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Genital Diseases, Female, Ovarian Diseases
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
The purpose of this study is to determine the activity, tolerability and safety of Temsirolimus in women with ovarian cancer who progressed during the previous platinum chemotherapy alternatively within 6 months from completion…
- Conditions
- Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Endometrial Neoplasms
- Trial name
- NCT01460979
- Testing
- Temsirolimus
- Where
- 18 sites in Germany
- Volunteers
- 47 people
- Sponsor
- AGO Study Group
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
The purpose of this study is determine the highest dose of bortezomib, a new drug for graft-versus host disease prevention, that can be given in combination with sirolimus and Tacrolimus, without causing severe side effects.
- Conditions
- Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
- Trial name
- NCT00670423
- Testing
- Tacrolimus, Sirolimus, Bortezomib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jennifer E. Schwartz
Renal Failure
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
- Trial name
- NCT01976390
- Testing
- Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University
Breast Cancer
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and…
- Trial name
- NCT01111825
- Testing
- Temsirolimus, Neratinib
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 99 people
- Sponsor
- Puma Biotechnology, Inc.
Planned Kidney Transplantation
Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation
Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients.
- Trial name
- NCT01706471
- Testing
- Everolimus + Low dose CsA +PD, Myfortic+ Standard CsA + PD
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Epilepsy and Focal Cortical Dysplasia II
A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
This is a prospective, randomized, double-blind, placebo-controlled cross over study designed to evaluate the efficacy and safety of everolimus (trough 5-15 ng/mL) given as adjunctive therapy in patients with focal cortical…
- Trial name
- NCT03198949
- Testing
- Afinitor (everolimus)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Yonsei University
Arterial Occlusive Diseases
YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study
The purpose of this study is to compare the effectiveness of the treatment with balloon-expandable YUKON-BTX-Sirolimus-eluting stent over the treatment with YUKON-BTX uncoated stent in patients with ischemic infrapopliteal…
- Trial name
- YUKON-BTK (NCT00664963)
- Testing
- Implantation of YUKON Sirolimus-eluting Stent, Implantation of YUKON Stent (uncoated)
- Where
- 3 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Herz-Zentrums Bad Krozingen
End-stage Renal Disease
Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
This 2 x 2 sequential factorial study evaluates two potential improvements to the standard immunosuppression regimen used at the investigators' institution to prevent rejection of transplanted kidneys.
- Trial name
- NCT00556933
- Testing
- rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Nebraska
Sarcoma
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
This study will examine the safety and effectiveness of stem cell transplantation for treating patients with sarcomas (tumors of the bone, nerves, or soft tissue).
- Trial name
- NCT00043979
- Testing
- F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IV Melanoma
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00281957
- Testing
- sorafenib tosylate, tipifarnib, temsirolimus
- Where
- 173 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Malignant Carcinoma
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
The primary purpose of this study is to identify the maximum tolerated dose(s) (MTD) of neratinib in combination with temsirolimus in subjects with solid tumors.
- Trial name
- NCT00838539
- Testing
- Neratinib, Temsirolimus
- Where
- 5 sites in United States, France
- Volunteers
- 63 people
- Sponsor
- Puma Biotechnology, Inc.
Testicular Cancer, Germ Cell Cancer
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
The purpose of this study is to determine whether the drug everolimus is effective in the treatment of patients with relapsed cancer of the testis.
- Trial name
- RADIT (NCT01242631)
- Testing
- Everolimus
- Where
- 8 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Hannover Medical School
Coronary Artery Disease
Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
The main objective of this study is to assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion restenosis in patients with de novo native coronary artery lesions.
- Trial name
- NCT00232739
- Testing
- CYPHER Sirolimus-eluting Coronary Stent
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Pancreatic Neuroendocrine Tumor
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
This research study will test the safety of RAD001 in combination with temozolomide.
- Trial name
- NCT00576680
- Testing
- RAD001, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Background: Stem cell transplantation from a partially matched donor can lead to graft-versus-host disease (GVHD). Researchers want to learn how to improve these transplantations.
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02226861
- Testing
- CliniMACS CD34 selection system, ULD IL-2
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
End Stage Renal Failure With Renal Transplant
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
The immune system is the body's defense against infection and other disease. After transplantation, the body sees the new organ as "foreign" and tries to destroy or "reject" it.
- Trial name
- NCT01653847
- Testing
- Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Northwestern University
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.